APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Attenuated Live Vaccine

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Selected research

Industry Growth & Trends

Global Varicella Attenuated Live Vaccine Industry Growth and Trends Forecast to 2032

21 December 202598 pages

Choose your research edition.

Industry ResearchVaricella Attenuated Live Vaccine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Attenuated Live Vaccine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Varicella Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Attenuated Live Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

Read the full market overview

Report Scope

This report provides a structured, data-driven view of the global Varicella Attenuated Live Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Varicella Attenuated Live Vaccine market size, estimates, and forecasts are presented in terms of sales volume (k doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Varicella Attenuated Live Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant toVaricella Attenuated Live Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Varicella Attenuated Live Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Varicella Attenuated Live Vaccine Market by Company

Merck

BCHT

Shanghai Institute

GSK

Keygen

Green Cross

Biken

Shanghai Rongsheng Biotech

Changchun Changsheng Life Sciences Limited

Varicella Attenuated Live Vaccine Segment by Type

Monovalent Vaccine

Combination Vaccine

Varicella Attenuated Live Vaccine Segment by Application

Kids Injection

Adults Injection

Varicella Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Monovalent Vaccine Table 2. Major Company of Combination Vaccine Table 3. Global Varicella Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 5. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Varicella Attenuated Live Vaccine Price by Type (2021-2026) & (USD/dose) Table 9. Global Varicella Attenuated Live Vaccine Sales by Type (2027-2032) & (k doses) Table 10. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Varicella Attenuated Live Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Varicella Attenuated Live Vaccine Price by Type (2027-2032) & (USD/dose) Table 14. North America Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 15. North America Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 17. Europe Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 19. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 21. Latin America Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 23. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Varicella Attenuated Live Vaccine Industry Trends Table 25. Varicella Attenuated Live Vaccine Industry Drivers Table 26. Varicella Attenuated Live Vaccine Industry Opportunities and Challenges Table 27. Varicella Attenuated Live Vaccine Industry Restraints Table 28. Global Varicella Attenuated Live Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Varicella Attenuated Live Vaccine Sales by Company (2021-2026) & (k doses) Table 31. Global Varicella Attenuated Live Vaccine Sales Share by Company (2021-2026) Table 32. Global Varicella Attenuated Live Vaccine Market Price by Company (2021-2026) & (USD/dose) Table 33. Global Varicella Attenuated Live Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Varicella Attenuated Live Vaccine Major Company Production Sites and Headquarters Table 35. Global Varicella Attenuated Live Vaccine Company, Product Type & Application Table 36. Global Varicella Attenuated Live Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Varicella Attenuated Live Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Varicella Attenuated Live Vaccine Sales by Region (2021-2026) & (k doses) Table 41. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Varicella Attenuated Live Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 45. Global Varicella Attenuated Live Vaccine Sales by Region (2027-2032) & (k doses) Table 46. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Varicella Attenuated Live Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2027-2032) Table 50. Global Varicella Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 52. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Varicella Attenuated Live Vaccine Price by Application (2021-2026) & (USD/dose) Table 56. Global Varicella Attenuated Live Vaccine Sales by Application (2027-2032) & (k doses) Table 57. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Varicella Attenuated Live Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Varicella Attenuated Live Vaccine Price by Application (2027-2032) & (USD/dose) Table 61. North America Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 62. North America Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 64. Europe Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 66. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 68. Latin America Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 70. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 74. Merck Varicella Attenuated Live Vaccine Product Portfolio Table 75. Merck Recent Development Table 76. BCHT Company Information Table 77. BCHT Business Overview Table 78. BCHT Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 79. BCHT Varicella Attenuated Live Vaccine Product Portfolio Table 80. BCHT Recent Development Table 81. Shanghai Institute Company Information Table 82. Shanghai Institute Business Overview Table 83. Shanghai Institute Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 84. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio Table 85. Shanghai Institute Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 89. GSK Varicella Attenuated Live Vaccine Product Portfolio Table 90. GSK Recent Development Table 91. Keygen Company Information Table 92. Keygen Business Overview Table 93. Keygen Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 94. Keygen Varicella Attenuated Live Vaccine Product Portfolio Table 95. Keygen Recent Development Table 96. Green Cross Company Information Table 97. Green Cross Business Overview Table 98. Green Cross Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 99. Green Cross Varicella Attenuated Live Vaccine Product Portfolio Table 100. Green Cross Recent Development Table 101. Biken Company Information Table 102. Biken Business Overview Table 103. Biken Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 104. Biken Varicella Attenuated Live Vaccine Product Portfolio Table 105. Biken Recent Development Table 106. Shanghai Rongsheng Biotech Company Information Table 107. Shanghai Rongsheng Biotech Business Overview Table 108. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 109. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio Table 110. Shanghai Rongsheng Biotech Recent Development Table 111. Changchun Changsheng Life Sciences Limited Company Information Table 112. Changchun Changsheng Life Sciences Limited Business Overview Table 113. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 114. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio Table 115. Changchun Changsheng Life Sciences Limited Recent Development Table 116. North America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 117. North America Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 118. North America Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 119. North America Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 120. North America Varicella Attenuated Live Vaccine Sales Market Share Forecast by Country (2027-2032) Table 121. North America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America Varicella Attenuated Live Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 123. North America Varicella Attenuated Live Vaccine Market Share by Country (2021-2026) Table 124. North America Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America Varicella Attenuated Live Vaccine Market Share Forecast by Country (2027-2032) Table 126. Europe Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 127. Europe Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 128. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 129. Europe Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 130. Europe Varicella Attenuated Live Vaccine Sales Market Share Forecast by Country (2027-2032) Table 131. Europe Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe Varicella Attenuated Live Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe Varicella Attenuated Live Vaccine Market Share by Country (2021-2026) Table 134. Europe Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe Varicella Attenuated Live Vaccine Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 138. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 140. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Varicella Attenuated Live Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific Varicella Attenuated Live Vaccine Market Share by Country (2021-2026) Table 144. Asia-Pacific Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific Varicella Attenuated Live Vaccine Market Share Forecast by Country (2027-2032) Table 146. Latin America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 147. Latin America Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 148. Latin America Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 149. Latin America Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 150. Latin America Varicella Attenuated Live Vaccine Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America Varicella Attenuated Live Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America Varicella Attenuated Live Vaccine Market Share by Country (2021-2026) Table 154. Latin America Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America Varicella Attenuated Live Vaccine Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 158. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 160. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa Varicella Attenuated Live Vaccine Market Share by Country (2021-2026) Table 164. Middle East and Africa Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa Varicella Attenuated Live Vaccine Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Varicella Attenuated Live Vaccine Distributors List Table 169. Varicella Attenuated Live Vaccine Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Varicella Attenuated Live Vaccine Image Figure 2. Global Varicella Attenuated Live Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Attenuated Live Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Varicella Attenuated Live Vaccine Sales (2021-2032) & (k doses) Figure 5. Monovalent Vaccine Image Figure 6. Global Monovalent Vaccine Sales YoY Growth (2021-2032) & (k doses) Figure 7. Combination Vaccine Image Figure 8. Global Combination Vaccine Sales YoY Growth (2021-2032) & (k doses) Figure 9. Global Varicella Attenuated Live Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Varicella Attenuated Live Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Varicella Attenuated Live Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Varicella Attenuated Live Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Varicella Attenuated Live Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Varicella Attenuated Live Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Kids Injection Image Figure 24. Global Kids Injection Sales YoY Growth (2021-2032) & (k doses) Figure 25. Adults Injection Image Figure 26. Global Adults Injection Sales YoY Growth (2021-2032) & (k doses) Figure 27. Global Varicella Attenuated Live Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Varicella Attenuated Live Vaccine Market Share by Application 2025 VS 2032 Figure 29. North America Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application in 2025 Figure 30. North America Varicella Attenuated Live Vaccine Sales Market Share in Value by Application in 2025 Figure 31. Europe Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Varicella Attenuated Live Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Varicella Attenuated Live Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Varicella Attenuated Live Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share in Value by Application in 2025 Figure 39. North America Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 40. North America Varicella Attenuated Live Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Varicella Attenuated Live Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 44. Europe Varicella Attenuated Live Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Varicella Attenuated Live Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 48. Asia-Pacific Varicella Attenuated Live Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Varicella Attenuated Live Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 52. Latin America Varicella Attenuated Live Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Varicella Attenuated Live Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 56. Middle East and Africa Varicella Attenuated Live Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Varicella Attenuated Live Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Varicella Attenuated Live Vaccine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Varicella Attenuated Live Vaccine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccine
  • Combination Vaccine
Applications
  • Kids Injection
  • Adults Injection
Companies covered
  • Merck
  • BCHT
  • Shanghai Institute
  • GSK
  • Keygen
  • Green Cross
  • Biken
  • Shanghai Rongsheng Biotech
  • Changchun Changsheng Life Sciences Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Varicella Attenuated Live Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Varicella Attenuated Live Vaccine Market by Type
  6. 1.3.1 Monovalent Vaccine
  7. 1.3.2 Combination Vaccine
  8. 1.4 Global Varicella Attenuated Live Vaccine Market Size by Type
  9. 1.4.1 Global Varicella Attenuated Live Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Varicella Attenuated Live Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Varicella Attenuated Live Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Varicella Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Attenuated Live Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Varicella Attenuated Live Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Varicella Attenuated Live Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Varicella Attenuated Live Vaccine Price (2021-2026)
  4. 3.4 Global Varicella Attenuated Live Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Varicella Attenuated Live Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Varicella Attenuated Live Vaccine Company, Product Type & Application
  7. 3.7 Global Varicella Attenuated Live Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Varicella Attenuated Live Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Varicella Attenuated Live Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Varicella Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Attenuated Live Vaccine Regional Status and Outlook
  1. 4.1 Global Varicella Attenuated Live Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Varicella Attenuated Live Vaccine Historic Market Size by Region
  3. 4.2.1 Global Varicella Attenuated Live Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Varicella Attenuated Live Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Varicella Attenuated Live Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Varicella Attenuated Live Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Varicella Attenuated Live Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Varicella Attenuated Live Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Varicella Attenuated Live Vaccine by Application
  1. 5.1 Varicella Attenuated Live Vaccine Market by Application
  2. 5.1.1 Kids Injection
  3. 5.1.2 Adults Injection
  4. 5.2 Global Varicella Attenuated Live Vaccine Market Size by Application
  5. 5.2.1 Global Varicella Attenuated Live Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Varicella Attenuated Live Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Varicella Attenuated Live Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 BCHT
  8. 6.2.1 BCHT Company Information
  9. 6.2.2 BCHT Business Overview
  10. 6.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
  12. 6.2.5 BCHT Recent Developments
  13. 6.3 Shanghai Institute
  14. 6.3.1 Shanghai Institute Company Information
  15. 6.3.2 Shanghai Institute Business Overview
  16. 6.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
  18. 6.3.5 Shanghai Institute Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Keygen
  26. 6.5.1 Keygen Company Information
  27. 6.5.2 Keygen Business Overview
  28. 6.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
  30. 6.5.5 Keygen Recent Developments
  31. 6.6 Green Cross
  32. 6.6.1 Green Cross Company Information
  33. 6.6.2 Green Cross Business Overview
  34. 6.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
  36. 6.6.5 Green Cross Recent Developments
  37. 6.7 Biken
  38. 6.7.1 Biken Company Information
  39. 6.7.2 Biken Business Overview
  40. 6.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
  42. 6.7.5 Biken Recent Developments
  43. 6.8 Shanghai Rongsheng Biotech
  44. 6.8.1 Shanghai Rongsheng Biotech Company Information
  45. 6.8.2 Shanghai Rongsheng Biotech Business Overview
  46. 6.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
  48. 6.8.5 Shanghai Rongsheng Biotech Recent Developments
  49. 6.9 Changchun Changsheng Life Sciences Limited
  50. 6.9.1 Changchun Changsheng Life Sciences Limited Company Information
  51. 6.9.2 Changchun Changsheng Life Sciences Limited Business Overview
  52. 6.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
  54. 6.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
7 North America by Country
  1. 7.1 North America Varicella Attenuated Live Vaccine Sales by Country
  2. 7.1.1 North America Varicella Attenuated Live Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Varicella Attenuated Live Vaccine Market Size by Country
  6. 7.2.1 North America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Varicella Attenuated Live Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Varicella Attenuated Live Vaccine Sales by Country
  2. 8.1.1 Europe Varicella Attenuated Live Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Varicella Attenuated Live Vaccine Market Size by Country
  6. 8.2.1 Europe Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Varicella Attenuated Live Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Varicella Attenuated Live Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Varicella Attenuated Live Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Varicella Attenuated Live Vaccine Sales by Country
  2. 10.1.1 South America Varicella Attenuated Live Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Varicella Attenuated Live Vaccine Market Size by Country
  6. 10.2.1 South America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Varicella Attenuated Live Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Varicella Attenuated Live Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Varicella Attenuated Live Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Varicella Attenuated Live Vaccine Value Chain Analysis
  2. 12.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Varicella Attenuated Live Vaccine Production Mode & Process
  7. 12.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Varicella Attenuated Live Vaccine Distributors
  10. 12.2.3 Varicella Attenuated Live Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst